Natural product-inspired synthesis of coumarin–chalcone hybrids as potential anti-breast cancer agents
Frontiers in Pharmacology · 06.09.2023 · 14
DOI: 10.3389/fphar.2023.1231450 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 06.09.2023. Verfasst von Nabil A Alhakamy und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Twelve novel neo-tanshinlactone–chalcone hybrid molecules were constructed through a versatile methodology involving the Horner–Wadsworth–Emmons (HWE) olefination of 4-formyl- 2H -benzo [ h ]chromen-2-ones and phosphonic acid diethyl esters, as the key step, and evaluated for anticancer activity against a series of four breast cancers and their related cell lines, viz. MCF-7 (ER + ve), MDA-MB-231 (ER-ve), HeLa (cervical cancer), and Ishikawa (endometrial cancer). The title compounds showed excellent to moderate in vitro anti-cancer activity in a range of 6.8–19.2 µM (IC 50 ). Compounds 30 ( IC 50 = 6.8 µM and MCF-7; IC 50 = 8.5 µM and MDA-MB-231) and 31 ( IC 50 = 14.4 µM and MCF-7; IC 50 = 15.7 µM and MDA-MB-231) exhibited the best activity with compound 30 showing more potent activity than the standard drug tamoxifen. Compound 30 demonstrated a strong binding affinity with tumor necrosis factor α (TNF-α) in molecular docking studies. This is significant because TNFα is linked to MCF-7 cancer cell lines, and it enhances luminal breast cancer cell proliferation by upregulating aromatase. Additionally, virtual ADMET studies confirmed that hybrid compounds 30 and 31 met Lipinski’s rule; displayed high bioavailability, excellent oral absorption, favorable albumin interactions, and strong penetration capabilities; and improved blood–brain barrier crossing. Based on the aforementioned results, compound 30 has been identified as a potential anti-breast cancer lead molecule.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.
- Mohamed Saeed Tamer Chair for Pharmaceutical Industries, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.
- Center of Excellence for Drug Research and Pharmaceutical Industries, King Abdulaziz University, Jeddah, Saudi Arabia.
- Department of Chemistry, University of Allahabad, Prayagraj, India.
- Department of Chemistry, Government Raza Post Graduate College, Rampur, India.
- M. J. P. Rohilkhand University, Bareilly, India.
Zitieren
APA
Alhakamy, N. A., Saquib, M., Sanobar, Khan, M. F., Ansari, W. A., Arif, D. O., Irfan, M., Khan, M. I., & Hussain, M. K. (2023). Natural product-inspired synthesis of coumarin–chalcone hybrids as potential anti-breast cancer agents. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1231450
Vancouver
Alhakamy NA, Saquib M, Sanobar, Khan MF, Ansari WA, Arif DO, et al. Natural product-inspired synthesis of coumarin–chalcone hybrids as potential anti-breast cancer agents. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1231450
BibTeX
@article{Alhakamy2023,
author = {Alhakamy, Nabil A and Saquib, Mohammad and Sanobar and Khan, Mohammad Faheem and Ansari, Waseem Ahmad and Arif, Deema O and Irfan, Mohammad and Khan, Mohammad Imran and Hussain, Mohd Kamil},
title = {Natural product-inspired synthesis of coumarin–chalcone hybrids as potential anti-breast cancer agents},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {14},
doi = {10.3389/fphar.2023.1231450}
}
EUVIMED